Continued Process Verification in Pharma: A Practical Guide to Ongoing Process Validation

Moving Beyond Validation Completion: How CPV Ensures Pharmaceutical Processes Remain in a State of Control

In pharmaceutical manufacturing, validation is no longer considered a one-time activity completed after successful process qualification batches. Regulatory expectations have evolved toward a lifecycle approach, where manufacturers must continuously demonstrate that their processes remain capable of consistently producing safe, effective and high-quality medicines.

This is where Continued Process Verification becomes a critical element of the pharmaceutical quality system, connecting initial validation activity with ongoing process assurance.

CPV is not just another compliance requirement. It is a proactive strategy used to identify process variability, prevent failures, improve manufacturing performance and maintain regulatory confidence throughout the commercial lifecycle of a product.

Within the process validation lifecycle, validation is generally understood as three connected stages:

Stage 1 – Process Design
Stage 2 – Process Qualification
Stage 3 – Continued Process Verification

Continued Process Verification represents the ongoing monitoring and evaluation phase that confirms a validated process continues to operate within an established state of control.

What is Continued Process Verification in Pharma?

Continued Process Verification is a systematic programme used to collect, analyse and evaluate manufacturing process data to ensure that the process remains capable of consistently delivering products that meet predefined quality attributes.

Unlike traditional validation activities that focus on specific validation batches, CPV continuously evaluates real-world commercial manufacturing performance. This makes it central to ongoing process validation, because it helps confirm that the process remains reliable after initial qualification has been completed.

A successful CPV programme answers key questions:

• Is the manufacturing process still operating within validated limits?
• Are Critical Process Parameters remaining stable?
• Are Critical Quality Attributes consistently achieved?
• Are process variations increasing over time?
• Are corrective actions required before failures occur?

According to regulatory expectations, CPV should use product and process knowledge, risk management principles and statistical evaluation to monitor process performance throughout the product lifecycle.

Why CPV in Pharma Matters for Maintaining a Validated State

CPV matters because process validation approval does not guarantee that a manufacturing process will remain consistent forever. Over time, factors such as raw material variability, equipment ageing, operator differences, environmental changes, supplier variations and process improvements can influence process performance.

Continued Process Verification helps pharmaceutical manufacturers maintain the validated state by continuously monitoring and evaluating process performance. This provides evidence that the process remains within the validated state throughout the product lifecycle.

A robust CPV programme serves as the connection between initial validation activities and ongoing process assurance.

Early Detection of Process Drift

A key advantage of CPV is its ability to identify early signs of process drift before they impact product quality or result in deviations, batch failures or regulatory concerns.

Through data trending and statistical analysis, CPV enables manufacturers to detect:

• Changes in process parameters
• Shifts in analytical results
• Equipment performance issues
• Emerging variability patterns
• Increasing deviation trends
• Movement toward alert or action limits

By enabling proactive decision-making, CPV helps organisations move from a reactive quality approach to a preventive strategy focused on process stability, product quality and continuous improvement.

The result is improved product quality, fewer deviations, reduced risks and greater operational efficiency.

Supporting Regulatory Compliance and Inspection Readiness

Regulatory agencies expect pharmaceutical manufacturers to demonstrate ongoing control and monitoring of validated processes throughout the product lifecycle.

An effective CPV programme provides documented evidence of process performance through:

• Defined monitoring strategies
• Appropriate statistical evaluation
• Justified alert and action limits
• Effective trending mechanisms
• Periodic review of CPPs and CQAs
• Clear escalation pathways when trends indicate concern

By maintaining a robust CPV system, pharmaceutical companies can strengthen GMP inspection readiness, demonstrate regulatory compliance and ensure continued confidence in their manufacturing processes.

The outcome is regulatory compliance, inspection readiness and sustained process assurance.

Building an Effective CPV Programme: A Practical Approach

A strong CPV programme should be structured, risk-based and aligned with the wider pharmaceutical quality system and the organisation’s overall Validation Master Plan. It should not simply collect data for the sake of compliance. It should provide meaningful insight into process performance and support informed quality decisions.

The following steps provide a practical approach to building an effective CPV programme.

Step 1: Define Critical Process Parameters and Critical Quality Attributes

A successful CPV programme starts with a clear understanding of the manufacturing process and the factors that impact product quality.

Pharmaceutical companies should define Critical Quality Attributes, such as assay, dissolution, sterility, impurity profile and particle size distribution, along with Critical Process Parameters, including temperature, mixing speed, granulation time, compression force and filling parameters.

Clearly defining CPPs and CQAs ensures that process performance monitoring is focused on the factors that have the greatest impact on product quality, patient safety and process consistency.

Step 2: Develop a Risk-Based Monitoring Plan

An effective CPV strategy requires a risk-based monitoring approach to determine which process parameters need closer oversight.

Companies should prioritise:

• High-risk process steps
• Quality-impacting parameters
• Historical process trends
• Equipment-related risks
• Known sources of variability
• Parameters linked to previous deviations, OOS or OOT events

This ensures monitoring activity is focused where it adds the most value. High-risk areas may require tighter controls, more frequent review or more detailed statistical analysis, while lower-risk parameters may be monitored at a reduced frequency where scientifically justified.

A risk-based monitoring plan helps teams use resources effectively while maintaining confidence that the process remains in a state of control.

Step 3: Use Statistical Process Control and Data Analysis

CPV is not only about collecting process data. It is about transforming data into meaningful insights that support decision-making.

Statistical tools such as control charts, process capability analysis, trend analysis, regression analysis and statistical process control help identify process variations and potential risks.

These tools allow teams to detect whether changes are random, expected variation or an early signal that the process may be drifting from its validated state.

Effective data analysis can help identify:

• Emerging process variability
• Gradual movement toward specification limits
• Repeated minor shifts in performance
• Patterns across batches, products, equipment or sites
• Opportunities for process improvement
• Areas where corrective or preventive action may be required

When used correctly, statistical process control supports proactive quality management and helps manufacturers maintain an ongoing state of control.

Step 4: Create a Robust CPV Report System

A well-structured CPV report provides a comprehensive view of process performance and ongoing state of control.

It typically includes:

• Manufacturing performance evaluation
• Batch history
• Yield trends
• Deviations
• OOS and OOT events
• CPP trends
• Equipment performance
• Process variability
• CQA trends
• Stability impact
• Market complaint evaluation

A strong CPV report system supports structured process performance monitoring, helping teams detect trends, investigate variability and maintain confidence in the validated state.

The report should not simply present data. It should explain what the data means, whether the process remains in control, and whether any actions are required to protect product quality and patient safety.

The Future of CPV: From Monitoring to Predictive Quality

Modern pharmaceutical manufacturing is moving toward advanced analytics, automation and real-time monitoring.

Future-focused CPV programmes are incorporating:

• Process analytical technology
• Manufacturing data platforms
• Artificial intelligence-based trend detection
• Digital manufacturing systems
• Real-time process monitoring
• Automated alerts and dashboards

The goal is to move from:

“What happened?”

to

“What is likely to happen, and how can we prevent it?”

This evolution supports the principles of Quality by Design, where process understanding and risk-based control strategies drive consistent product quality.

As digital systems and connected manufacturing data become more advanced, CPV can move beyond retrospective review and become a proactive part of quality decision-making. This supports stronger process performance monitoring, earlier intervention and greater confidence in the validated state.

Maintaining a State of Control Through Continued Process Verification

Continued Process Verification is no longer just a regulatory expectation. It is a strategic approach for maintaining process reliability, ensuring consistent product quality and achieving operational excellence.

By integrating risk-based monitoring, statistical process control, structured CPV reporting and advanced technologies, pharmaceutical companies can maintain a continuous state of control and confidently manage their manufacturing processes throughout the product lifecycle.

A strong CPV programme helps ensure that validation does not end once qualification is complete. Instead, it becomes part of an ongoing process validation strategy that supports compliance, process understanding, inspection readiness and continuous improvement.

For pharmaceutical manufacturers, Continued Process Verification provides the evidence needed to show that processes remain capable, controlled and aligned with quality expectations over time. This is what turns validation from a point-in-time activity into a lifecycle approach that supports long-term product quality and patient safety.

Is your CPV programme providing meaningful insight—or simply collecting data?

Read the full guide to explore how a practical, risk-based approach can help maintain process control, identify drift earlier and support ongoing GMP compliance.